Cargando…
Plerixafor is superior to conventional chemotherapy for first-line stem cell mobilisation, and is effective even in heavily pretreated patients
This study (PHANTASTIC) compares first-line plerixafor with granulocyte colony-stimulating factor (G-CSF) in 98 myeloma and lymphoma patients with 151 historic controls mobilised by conventional chemotherapy+G-CSF. Eleven patients developed mild transient symptoms possibly related to plerixafor. No...
Autores principales: | Clark, R E, Bell, J, Clark, J O, Braithwaite, B, Vithanarachchi, U, McGinnity, N, Callaghan, T, Francis, S, Salim, R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4220652/ https://www.ncbi.nlm.nih.gov/pubmed/25360901 http://dx.doi.org/10.1038/bcj.2014.79 |
Ejemplares similares
-
Plerixafor
por: Slater, Susan
Publicado: (2012) -
Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma
por: Richardson, Paul G., et al.
Publicado: (2021) -
The role of idecabtagene vicleucel in patients with heavily
pretreated refractory multiple myeloma
por: Oriol, Albert, et al.
Publicado: (2021) -
Long-lasting effect of belantamab mafodotin in heavily pretreated multiple myeloma
por: Gil-Sierra, Manuel David, et al.
Publicado: (2022) -
To mobilise or not to mobilise: is that the right question?
por: Hodgson, Carol L., et al.
Publicado: (2023)